URL has been copied successfully!
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported financial results for the first quarter after the market close on Monday. Here’s a rundown of the report.
- Vertex Pharmaceuticals stock is holding steady today. What’s the outlook for VRTX shares?
Vertex Q1 Highlights
Vertex reported first-quarter revenue of $2.99 billion, missing analyst estimates of $3.03 billion, according to Benzinga Pro. The company posted first-quarter adjusted earnings of $4.47 per share, beating estimates of $4.31 per share.
Total revenue was up 8% on a year-over-year basis, primarily driven by cystic fibrosis therapies and growth from diversification into additional disease areas.
“CASGEVY and JOURNAVX delivered more than 25 percent of our growth this …
Please follow us:
